Bluebird bio Inc

-0.45 (-5.83%)
Products, Regulatory, Other Pre-Announcement

bluebird Bio Inc - Full-Year 2022 Cash Burn Is Expected To Be Less Than $400 Million

Published: 01/11/2022 12:14 GMT
Bluebird bio Inc (BLUE) - Full-year 2022 Cash Burn is Expected to Be Less Than $400 Million.
Bluebird Bio - Plans to Explore Sale of Priority Review Vouchers That Would Be Expected to Be Issued With U.S. Approvals of Blas for Beti-cel, Eli-cel.
About $150-200 Million in Non-dilutive Cash Inflows Could Potentially Be Realized From Sale of Some Priority Review Vouchers.
Potentially Realizing About $150-200 Million in Non-dilutive Cash Inflows, Would Extend Current Cash Runway Into 2023.
An FDA Advisory Committee to Discuss Biologics License Application (bla) for Beti-cel is Anticipated on March 9, 2022.
Bluebird Bio - Evaluating Impact, If Any, Ongoing Partial Clinical Hold of Lovo-cel for Those Under 18 May Have on Projected Timing for Bla Submission.
Expects to Complete Manufacturing of Commercial Drug Product Validation Lots for Lovo-cel , for Sickle Cell Disease in Mid-2022.